Skip to content

Research at St Andrews

In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract

Research output: Contribution to journalArticlepeer-review

Standard

In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. / Siriyong, Thanyaluck; Ontong, Julalak Chorachoo; Leejae, Sukanlaya; Suwalak, Sakol; Coote, Peter John; Voravuthikunchai, Supayang Piyawan.

In: Toxicology Reports, Vol. 7, 31.07.2020, p. 919-924.

Research output: Contribution to journalArticlepeer-review

Harvard

Siriyong, T, Ontong, JC, Leejae, S, Suwalak, S, Coote, PJ & Voravuthikunchai, SP 2020, 'In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract', Toxicology Reports, vol. 7, pp. 919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

APA

Siriyong, T., Ontong, J. C., Leejae, S., Suwalak, S., Coote, P. J., & Voravuthikunchai, S. P. (2020). In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. Toxicology Reports, 7, 919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

Vancouver

Siriyong T, Ontong JC, Leejae S, Suwalak S, Coote PJ, Voravuthikunchai SP. In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. Toxicology Reports. 2020 Jul 31;7:919-924. https://doi.org/10.1016/j.toxrep.2020.07.013

Author

Siriyong, Thanyaluck ; Ontong, Julalak Chorachoo ; Leejae, Sukanlaya ; Suwalak, Sakol ; Coote, Peter John ; Voravuthikunchai, Supayang Piyawan. / In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract. In: Toxicology Reports. 2020 ; Vol. 7. pp. 919-924.

Bibtex - Download

@article{4ec4fcfd205847378d44ecd6301fbeec,
title = "In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract",
abstract = "BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.",
keywords = "Toxicity, Rhodomyrtone, Invertebrate, Vertebrate",
author = "Thanyaluck Siriyong and Ontong, {Julalak Chorachoo} and Sukanlaya Leejae and Sakol Suwalak and Coote, {Peter John} and Voravuthikunchai, {Supayang Piyawan}",
note = "This research was funded by the Thailand Research Fund Senior Research Scholar (Grant number RTA6180006).",
year = "2020",
month = jul,
day = "31",
doi = "10.1016/j.toxrep.2020.07.013",
language = "English",
volume = "7",
pages = "919--924",
journal = "Toxicology Reports",
issn = "2214-7500",
publisher = "Elsevier Scientific Publishers Ireland",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract

AU - Siriyong, Thanyaluck

AU - Ontong, Julalak Chorachoo

AU - Leejae, Sukanlaya

AU - Suwalak, Sakol

AU - Coote, Peter John

AU - Voravuthikunchai, Supayang Piyawan

N1 - This research was funded by the Thailand Research Fund Senior Research Scholar (Grant number RTA6180006).

PY - 2020/7/31

Y1 - 2020/7/31

N2 - BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.

AB - BackgroundRhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.Material and MethodsSafety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.ResultsTreatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.ConclusionsAs the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.

KW - Toxicity

KW - Rhodomyrtone

KW - Invertebrate

KW - Vertebrate

U2 - 10.1016/j.toxrep.2020.07.013

DO - 10.1016/j.toxrep.2020.07.013

M3 - Article

VL - 7

SP - 919

EP - 924

JO - Toxicology Reports

JF - Toxicology Reports

SN - 2214-7500

ER -

Related by author

  1. Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition

    Siriyong, T., Murray, R. M., Bidgood, L. E., Young, S. A., Wright, F., Parcell, B. J., Voravuthikunchai, S. P. & Coote, P. J., 24 Jun 2019, In: Scientific Reports. 9, 13 p., 9098.

    Research output: Contribution to journalArticlepeer-review

ID: 269483823

Top